Signs a collaboration agreement with Safety Syringes of the U.S. safety first: Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon, launching the drug delivery system in Bangalore on Wednesday. Biocon launched pre-filled syringes for delivering two life-saving drugs manufactured by it. The company has entered into a collaboration agreement with Safety Syringes of the U.S. which holds the patent for the retractable device. Two drugs, Erythropoietin, which is meant for patients suffering from renal disease, and granulocyte-colony stimulation factor, meant for cancer patients, are available for delivery through the new devices. Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon, said pre-filled syringes were useful for self-injecting patients because they enhance safety. Ms. Mazumdar said "the convenience product' enhances safety, while offering a "novel and innovative product at an affordable price.' She said the Indian market for pre-filled syringes was valued at about Rs. 200-300 crore. She said the market is "growing at double-digit rates.' The company aims for a market share of about 30 per cent in the next few years. Biocon's agreement with Safety Syringes allowed it to market the product in other parts of the world, Ms. Mazumdar said. The company, she said, planned to launch a similar device for delivering insulin for diabetics in three to six months.